Latest news and press releases about Pyxis Oncology, Inc. (PYXS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
Price
| Price | $3.34 |
| Market Cap | $212M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 19.38 |
| EV / EBITDA | -2.94 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -215.23% |
| Return on Invested Capital | -314.66% |
| Return on Assets | -161.55% |
| Gross Margin | 99.76% |
| Operating Margin | -834.44% |
| Net Margin | -803.83% |
Related companies: AVIR · CRBU · ENTA · FHTX · HUMA · IMRX · TNYA
Explore sector: Healthcare · Biotechnology
More sections of PYXS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks